In one of the studies involving such inhibitors, the effectiveness of anti-PD-1 nivolumab in comparison to anti-VEGF monoclonal antibody bevacizumab was investigated in patients with first-time GBM recurrence [163]. This evidence concerns the gene PDCD1 and glioblastoma.